Topical Growth Factors and Wound Contraction in the Rat: Part II. Platelet-derived Growth Factor and Wound Contraction in Normal and Steroid-impaired Rats

Engrav, Loren H.; Richey, Karla J.; Kao, Chia Chi; Murray, Mark J.

doi:10.1097/00000637-198909000-00009

Cited by 18 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…0.05 versus vehicle group at this time point. showing that the agent has little effect on wound contraction in a rat full excision model [17,18] . The vehicle gel alone actually produced a more rapid closure of wounds than was observed in nontreated wounds, probably due to the benefi cial effect of moisture retention through the occlusive effect of the gel.…”

Section: Discussionmentioning

confidence: 97%

Accelerated Healing of Excisional Skin Wounds by PL 14736 in Alloxan-Hyperglycemic Rats<sup>1</sup>

Ševeljević-Jaran

Čužić

Dominis-Kramarić

et al. 2006

Skin Pharmacol Physiol

View full text Add to dashboard Cite

PL 14736 is a synthetic peptide, originally isolated from human gastric juice, that has anti-inflammatory and tissue-protective actions in experimental models of gastrointestinal inflammation. To investigate its possible benefit in poorly healing skin wounds, the effects of the topical application of PL 14736 in a gel formulation have been studied on full-thickness excisional wounds in rats, either healthy or made hyperglycemic by alloxan (175 mg/kg s.c.) 5 days previously. The effects of becaplermin gel (platelet-derived growth factor, PDGF-BB, Regranex^®), a standard therapy for diabetic foot ulcers, were investigated for comparison. Healing was evaluated for up to 7 days after wounding, using digital planimetry analysis, macroscopic scoring and histology. While healing was too rapid in healthy rats to observe enhancement by either treatment, in the hyperglycemic rats which exhibited delayed healing, PL 14736 (10–1,000 µg/wound) produced a dose-dependent acceleration of wound healing (determined by macroscopic scoring) equivalent at the highest doses to that observed with becaplermin. The beneficial effect on healing was associated with increased deposition of organized granulation tissue by day 7 for both PL 14736 and becaplermin, as determined histologically. PL 14736 tended to have a greater effect than becaplermin on the formation of granulation tissue containing mature collagen. Wound contraction, as measured by planimetry, was not significantly affected. In conclusion, topical PL 14736 produces a dose-dependent acceleration of deficient skin wound healing in hyperglycemic rats by facilitating granulation tissue formation, similar to the response seen with topical becaplermin, the standard therapy for diabetic skin wounds. PL 14736 may represent an alternative therapy for delayed wound healing, such as that seen with diabetic foot ulcers, without the proliferative concerns or immunogenicity associated with growth factors.

show abstract

Section: Discussionmentioning

confidence: 97%

Accelerated Healing of Excisional Skin Wounds by PL 14736 in Alloxan-Hyperglycemic Rats<sup>1</sup>

Ševeljević-Jaran

Čužić

Dominis-Kramarić

et al. 2006

Skin Pharmacol Physiol

View full text Add to dashboard Cite

show abstract

“…These results suggest that healing may be impaired by inflammatory mediators rather than inhibited by a deficiency of growth factors in these chronic wounds. (WOUND REP REG 2000;8: [13][14][15][16][17][18][19][20][21][22][23][24][25] Chronic venous disease is the sole or major contributing factor in 75% of patients with a chronic leg ulcer. 1 The treatment of this type of chronic wound alone has been estimated to consume between 1% and 2% of the total health care budget in a number of Western countries.…”

Section: Naomi J Trengove Phd a ; Helle Bielefeldt-ohmann Dvm Phdmentioning

confidence: 99%

Mitogenic activity and cytokine levels in non‐healing and healing chronic leg ulcers

Trengove

Bielefeldt‐Ohmann

Stacey

2000

Wound Repair Regeneration

371

283

View full text Add to dashboard Cite

The cause of impaired healing in chronic leg ulcers is not known. However, recent attempts to modify the healing process have focused on adding growth factors to stimulate healing and have failed to produce dramatic improvements in healing. This study used a unique model of chronic wound healing in humans to obtain wound fluid samples from chronic venous leg ulcers that had changed from a nonhealing to a healing phase. These samples were used to assess cytokine and growth factor levels, and mitogenic activity in these nonhealing and healing chronic wounds. The pro-inflammatory cytokines interleukin-1, interleukin-6 and tumor necrosis factor-alphawere found to be present in significantly higher concentrations in wound fluid from nonhealing compared to healing leg ulcers. There were detectable levels but, no significant change in the levels of platelet derived growth factor, epidermal growth factor, basic fibroblast growth factor or transforming growth factor-betaas ulcers healed. Wound fluid was added to fibroblasts in vitro to assess mitogenic activity. There was a significantly greater proliferative response to healing wound fluid samples compared to nonhealing samples. These results suggest that healing may be impaired by inflammatory mediators rather than inhibited by a deficiency of growth factors in these chronic wounds.

show abstract

“…First-strand synthesis was primed with a T7-(dT) 24 oligonucleotide primer containing a T7 RNA polymerase promoter sequence on the 5Ј end (Genset Oligos, La Jolla, CA). Second-strand products were cleaned (GeneChip Sample Cleanup Module; Affymetrix) and used as a template for in vitro transcription (IVT) with biotin-labeled nucleotides (Bioarray High Yield RNA Transcript Labeling Kit; Enzo Diagnostics, Farmingdale, NY).…”

Section: Sample Collection and Preparation Of Labeled Copy Rnamentioning

confidence: 99%

“…Although the rat is well established as a model of general, [23][24][25][26][27] corneal, 28 -30 and retinal 31 wound healing, the standard animal model for the investigation of wound healing and the scarring process after GFS has been the rabbit, primarily because of the size of the eye. [32][33][34][35][36][37][38][39] However, unlike the rat, there are no commercially available microarrays for the rabbit at this time.…”

mentioning

confidence: 99%

Microarray Analysis of the Failure of Filtering Blebs in a Rat Model of Glaucoma Filtering Surgery

Esson

Popp

Liu

et al. 2004

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

show abstract

Topical Growth Factors and Wound Contraction in the Rat: Part II. Platelet-derived Growth Factor and Wound Contraction in Normal and Steroid-impaired Rats

Cited by 18 publications

References 0 publications

Accelerated Healing of Excisional Skin Wounds by PL 14736 in Alloxan-Hyperglycemic Rats<sup>1</sup>

Accelerated Healing of Excisional Skin Wounds by PL 14736 in Alloxan-Hyperglycemic Rats<sup>1</sup>

Mitogenic activity and cytokine levels in non‐healing and healing chronic leg ulcers

Microarray Analysis of the Failure of Filtering Blebs in a Rat Model of Glaucoma Filtering Surgery

Contact Info

Product

Resources

About